> ## Content Index
> Fetch the complete content index at: https://acentricresearch.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AI × Drug Discovery: Junction Brief – November 2026
- URL: https://acentricresearch.com/research/ai-drug-discovery-brief-2026-11/
- Published: 2026-11-20T22:43:03.000Z
- Updated: 2026-11-21T09:39:50.000Z
- Author: Kevin Meyer
- Tags: junction-brief, ai-biotechnology

> Acentric Research is produced with AI tools under human review. The authors are not financial professionals, and nothing here is investment advice or a recommendation to buy or sell any security. AI analysis can be wrong; check every claim against its cited source.

This Brief summarizes the Junction Report [AI × Drug Discovery: The Intersection Ecosystem – November 2026](https://acentricresearch.com/research/ai-drug-discovery-2026-11/), published 2026-11-17\. It adds no new research; facts and figures are the report’s, as of 2026-11-17, and the sources the report cites are footnoted here. AI × Drug Discovery was the reference Junction of the [Landscape Report](https://acentricresearch.com/research/landscape-2026-11/#lists) and was not ranked there.

### Overview

Drug discovery is the early part of drug development: choosing a biological target, then finding and refining a molecule that acts on it. Artificial intelligence (AI) is used here in four ways: models trained on data that rank molecules or targets; algorithms that propose new molecules; programs that predict a protein’s three-dimensional shape from its sequence, such as AlphaFold; \[1\] and large pretrained models adapted to tasks such as these. \[2\]

What stands out is the gap between claims and results. FDA approved lirafugratinib on 2026-09-23\. Its developer names machine learning as one ingredient of its platform, and no filing the report found says AI designed the molecule; no approved molecule comes from a company that ties its molecule or platform to AI outright. The gain that companies claim is speed in reaching a drug candidate. The report found no sign yet that later, more costly stages go better: a sizeable share of candidates tied to AI have been stopped, and Phase 1 progress, the only later stage compared, could not be told apart from the industry’s. \[2\] Sources date from 2016 to 2026.

### Current state

**An approval.** FDA approved lirafugratinib (Lyrfigtu) on 2026-09-23 for adults with previously treated cholangiocarcinoma, a bile-duct cancer, with an FGFR2 gene fusion or other rearrangement. The application was filed by Elevar Therapeutics. \[3\] Relay Therapeutics, which developed the molecule as RLY-4008, licensed it to Elevar in December 2024\. \[4\] The registry lists a Phase 1/2 trial of RLY-4008\. \[5\] In its 2022 annual report Relay wrote that its Dynamo platform “combines advanced machine learning models and molecular dynamics simulations” with laboratory work (company claim); the report found no Relay filing that says AI or machine learning designed this molecule. \[6\]

**Late-stage trials.** Three candidates that their companies link to AI, through the molecule or the discovery platform, are in Phase 3 trials, according to ClinicalTrials.gov: rentosertib from Insilico Medicine, for idiopathic pulmonary fibrosis and run in China; bexobrutideg from Nurix Therapeutics; and GB-0895 from Generate Biomedicines. \[7\] In 2023 Insilico described another of its candidates, ISM5411, now in a Phase 2 trial, as “Designed by AI from scratch” and “developed by Chemistry42, Insilico’s generative AI engine for molecule development” (company claim). \[8\]

**Speed.** Six candidates have a company-stated time from the start of a program to a development candidate, the molecule taken into formal safety testing. The median is 11.5 months (10.5 on each candidate’s earliest statement). The comparison is a literature figure of 4.5 years for discovery research, from a 2010 study restated in 2016\. \[9\] Every stated time is a company claim, from companies that chose to publish it. The source for rentosertib’s 18 months is a paper by company staff. \[10\]\[2\]

**Who is involved.** Schrödinger describes its software platform as built on “rigorous, physics-based methods, combined with the rapid data processing and scaling advantages of machine learning” (company claim). \[11\] Large drugmakers work mostly through partnerships: the report found AI partnerships for at least 16 of the 20 largest drugmakers. Examples include Isomorphic Labs with Eli Lilly in 2024, with $45 million upfront and up to $1.7 billion in milestones (company claim), \[12\] and Nurix with Roche in 2026, with $700 million upfront and up to $2.3 billion in total payments, according to Nurix’s filing, which does not describe the deal in AI terms. \[13\]\[14\]

**What happened to the candidates.** The report followed 32 candidates that company documents of the time tied to AI and that were in trials by the end of 2023\. By 2026-11-17, 13 (40.6%) had been stopped under the report’s written rules; other cohort and outcome readings give 20.7% to 40.6%. Three of the 13 stops followed trial results. Two were COVID-19 antibodies whose emergency use authorizations FDA revoked, which the report says did not reflect how they were discovered; six were portfolio decisions. \[15\]\[16\] Of 20 candidates with a known Phase 1 outcome, 12 moved to Phase 2\. That is 60%, against 52% for the industry in 2011–2020 and an expected 10.3 of 20 matched by disease area; it is not distinguishable from the industry’s rate, and the sample is too small to rule out a sizeable difference either way. \[15\]\[17\]

### Opportunities

If discovery gets shorter and trials do not, the clinical and regulatory stages, 10.5 years by BIO’s figures, become most of the path to approval. \[17\] Registry estimates put the end of data collection in Phase 3 trials of five AI-linked candidates, two from companies that name AI as one ingredient of a platform, between April 2028 and October 2029; such estimates often slip. \[7\]\[14\] On the report’s arithmetic of filing and review times, an FDA decision on a molecule that companies tie to AI outright or to an AI-based platform would come no earlier than 2029–2030, assuming 6–18 months to prepare a filing. \[18\]\[2\] Too few candidates have resolved Phase 2 outcomes to say whether AI raises Phase 2 success; readouts over 2027–2029 could. \[2\]

### Challenges

- **Regulation.** FDA’s draft guidance on AI in drug development says that “the use of AI for the purposes of drug discovery is not in the scope of this guidance”. \[19\] The European Medicines Agency writes that AI in drug discovery “can be low regulatory impact if non-optimal performance only affects the developer”; if results feed evidence for review, non-clinical development principles apply. \[20\] In the report’s record, an AI-found molecule enters the same review as any other. Iambic Therapeutics discloses that it “cannot predict ... whether the FDA or other regulators will accept AI-derived data or analyses” it may submit. \[21\]
- **Validation.** A 2024 perspective states that AI models “are often developed to excel on retrospective benchmarks unlikely to anticipate their prospective performance”. \[22\]
- **Evidence.** The claimed speed gain rests on company statements. A recent industry baseline would test it. \[2\]
- **Capital.** Among twelve public filers, stated cash runway had a median of 1.55 years from the filing date; the range was 1.0–2.85 years; four state only a 12-month horizon, and none states a doubt about continuing as a going concern. \[23\]
- **Records lag decisions.** Nurix decided in August 2026 to stop zelebrudomide, while ClinicalTrials.gov still listed its trial as recruiting on 2026-11-17, so counts of stopped candidates are a floor. \[24\]\[2\]

### Data sources

- **ClinicalTrials.gov**, for trial phases, status and estimated dates. It lags company decisions. \[25\]
- **Drugs@FDA** (openFDA), for approvals. Search by molecule and code name as well as sponsor, because licensed molecules change sponsor. \[26\]\[2\]
- **SEC EDGAR** filings: annual reports, quarterly reports, prospectuses and Form 8-K deal notices, for what companies say about their platforms, deals, runway and risks. \[27\]
- **Company releases and annual reports of non-US listed companies**, for deal terms and pipeline status. They are company claims. \[2\]
- **FDA and EMA guidance**, for how regulators treat AI. \[19\]\[20\]
- **Europe PMC**, for peer-reviewed reviews of validation. \[28\]
- **No good source:** the role AI played in finding a given molecule can be checked only against the company’s own statements, not against internal records, and no recent public baseline for discovery time was found. \[2\]

### Changelog

- 2026-11-18: First published.

### Sources

1. Jumper J. et al., “Highly accurate protein structure prediction with AlphaFold,” *Nature*, 2021-07-15\. [doi.org](https://doi.org/10.1038/s41586-021-03819-2?ref=acentricresearch.com)(accessed 2026-11-18)
2. Acentric Research, “AI × Drug Discovery: The Intersection Ecosystem – November 2026”, 2026-11-17 (the Junction Report this Brief summarizes; see its sections “Method and limitations” and “Open questions”). [acentricresearch.com](https://acentricresearch.com/research/ai-drug-discovery-2026-11/) (accessed 2026-11-18)
3. U.S. Food and Drug Administration, approval letter for NDA 220425, Lyrfigtu (lirafugratinib), Elevar Therapeutics, 2026-09-23\. [accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda%5Fdocs/appletter/2026/220425Orig1s000ltr.pdf?ref=acentricresearch.com) (accessed 2026-11-18)
4. Relay Therapeutics, Form 10-K for fiscal 2025, filed 2026-02-26 (company claim). [sec.gov](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/rlay-20251231.htm?ref=acentricresearch.com) (accessed 2026-11-18)
5. ClinicalTrials.gov, NCT04526106 (RLY-4008, Phase 1/2). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04526106?ref=acentricresearch.com) (accessed 2026-11-18)
6. Relay Therapeutics, Form 10-K for fiscal 2022, filed 2023 (company claim). [sec.gov](https://www.sec.gov/Archives/edgar/data/1812364/000095017023004123/rlay-20221231.htm?ref=acentricresearch.com) (accessed 2026-11-18)
7. ClinicalTrials.gov, Phase 3 records: rentosertib, [NCT07687459](https://clinicaltrials.gov/study/NCT07687459?ref=acentricresearch.com); bexobrutideg, [NCT07516093](https://clinicaltrials.gov/study/NCT07516093?ref=acentricresearch.com); GB-0895, [NCT07276724](https://clinicaltrials.gov/study/NCT07276724?ref=acentricresearch.com); zovegalisib, [NCT06982521](https://clinicaltrials.gov/study/NCT06982521?ref=acentricresearch.com); aleniglipron, [NCT07654374](https://clinicaltrials.gov/study/NCT07654374?ref=acentricresearch.com) (accessed 2026-11-18)
8. Insilico Medicine, release of 2023-12-05 on ISM5411, verbatim copy on Kyodo News PR Wire (company claim). [kyodonewsprwire.jp](https://kyodonewsprwire.jp/release/202312053801?ref=acentricresearch.com) (accessed 2026-11-18)
9. Schuhmacher A., Gassmann O., Hinder M., “Changing R&D models in research-based pharmaceutical companies,” *Journal of Translational Medicine* 14:105, 2016, restating Paul S.M. et al. (2010). [doi.org](https://doi.org/10.1186/s12967-016-0838-4?ref=acentricresearch.com) (accessed 2026-11-18)
10. Ren F. et al., “A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models,” *Nature Biotechnology*, 2024-03-08 (authors include Insilico Medicine staff). [doi.org](https://doi.org/10.1038/s41587-024-02143-0?ref=acentricresearch.com) (accessed 2026-11-18)
11. Schrödinger, Form 10-K for fiscal 2025, filed 2026-02-25 (company claim). [sec.gov](https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/sdgr-20251231.htm?ref=acentricresearch.com) (accessed 2026-11-18)
12. Isomorphic Labs, “Isomorphic Labs announces strategic multi-target research collaboration with Lilly,” 2024-01-07 (company claim). [storage.googleapis.com](https://storage.googleapis.com/isomorphiclabs-website-public-artifacts/ISOMORPHIC%5FLABS%5FLILLY%5F07%5F01%5F24.pdf?ref=acentricresearch.com) (accessed 2026-11-18)
13. Nurix Therapeutics, Form 8-K, Item 1.01, filed 2026-06-08\. [sec.gov](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000030/nrix-20260606.htm?ref=acentricresearch.com) (accessed 2026-11-18)
14. Acentric Research, deal table and signposts in the AI × Drug Discovery data appendix (computed by the Junction Report’s scripts, not recomputed for this Brief). [acentricresearch.com](https://acentricresearch.com/report-data/#ai-and-drug-discovery-junction-report-november-2026) (accessed 2026-11-18)
15. Acentric Research, cohort outcomes and Phase 1 → 2 comparison in the AI × Drug Discovery data appendix (computed by the Junction Report’s scripts, not recomputed for this Brief). [acentricresearch.com](https://acentricresearch.com/report-data/#ai-and-drug-discovery-junction-report-november-2026) (accessed 2026-11-18)
16. U.S. Food and Drug Administration, “Emergency Use Authorization — Archived Information” (entries for bamlanivimab and etesevimab, and for bebtelovimab). [fda.gov](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization-archived-information?ref=acentricresearch.com) (accessed 2026-11-18)
17. BIO, Informa Pharma Intelligence and QLS Advisors, *Clinical Development Success Rates and Contributing Factors 2011–2020*, February 2021\. [go.bio.org](https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011%5F2020.pdf?ref=acentricresearch.com) (accessed 2026-11-18)
18. U.S. Food and Drug Administration, PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 through 2027\. [fda.gov](https://www.fda.gov/media/151712/download?ref=acentricresearch.com) (accessed 2026-11-18)
19. U.S. Food and Drug Administration, *Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products*, draft guidance, January 2025\. [fda.gov](https://www.fda.gov/media/184830/download?ref=acentricresearch.com) (accessed 2026-11-18)
20. European Medicines Agency, *Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle*, EMA/CHMP/CVMP/83833/2023, adopted 9 September 2024\. [ema.europa.eu](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle%5Fen.pdf?ref=acentricresearch.com) (accessed 2026-11-18)
21. Iambic Therapeutics, prospectus (Form 424B4), filed 2026-10-15 (company claim). [sec.gov](https://www.sec.gov/Archives/edgar/data/1997038/000119312526422865/iambic%5Finception%5F424b4.htm?ref=acentricresearch.com) (accessed 2026-11-18)
22. “Data-centric challenges with the application and adoption of artificial intelligence for drug discovery,” *Expert Opinion on Drug Discovery*, 2024 (abstract only). [doi.org](https://doi.org/10.1080/17460441.2024.2403639?ref=acentricresearch.com) (accessed 2026-11-18)
23. Acentric Research, runway as stated in twelve annual reports, in the AI × Drug Discovery data appendix (computed by the Junction Report’s scripts, not recomputed for this Brief). [acentricresearch.com](https://acentricresearch.com/report-data/#ai-and-drug-discovery-junction-report-november-2026) (accessed 2026-11-18)
24. Nurix Therapeutics, Form 10-Q for the quarter ended 2026-08-31, filed 2026-10-13\. [sec.gov](https://www.sec.gov/Archives/edgar/data/1549595/000154959526000049/nrix-20260831.htm?ref=acentricresearch.com) (accessed 2026-11-18)
25. National Library of Medicine, ClinicalTrials.gov. [clinicaltrials.gov](https://clinicaltrials.gov/?ref=acentricresearch.com) (accessed 2026-11-18)
26. U.S. Food and Drug Administration, openFDA Drugs@FDA bulk download. [download.open.fda.gov](https://download.open.fda.gov/drug/drugsfda/drug-drugsfda-0001-of-0001.json.zip?ref=acentricresearch.com) (accessed 2026-11-18)
27. US Securities and Exchange Commission, “Search Filings” (EDGAR). [sec.gov](https://www.sec.gov/search-filings?ref=acentricresearch.com) (accessed 2026-11-18)
28. Europe PMC, REST API. [ebi.ac.uk](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22drug%20discovery%22%20AND%20validation&format=json&ref=acentricresearch.com) (accessed 2026-11-18)